This offering is expected to close on or about July 3, 2025, subject to the satisfaction of customary closing conditions. ArriVent intends to use the net proceeds from the offering, together with its ...

The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys’ BV500 program into clinical candidates ...

Comment from CEO Yoshiyuki Aikawa “We are delighted to welcome Mr. Shinya Inoue as our new CMO. He brings exceptional ...

Breckenridge Distillery is a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global ...

VigRX Plus is the result of collaboration between herbal scientists, medical consultants, and nutraceutical engineers.

CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and ...

The aim of the stock option grants is to align the long-term interests of the board members and the Company. The relevant key terms and conditions of the Company´s Equity Incentive Plan approved by ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation ...

Spartan Capital Securities, LLC is acting as exclusive placement agent for the private placement. TroyGould PC is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to ...

The RSUs are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a restricted stock unit agreement covering the grant. LENSAR is a commercial-stage ...

Each stock option has a 10-year term and is subject to the terms and conditions of Akebia’s inducement award program and a stock option agreement covering the grant. Akebia Therapeutics, Inc. is a ...

CHARLESTOWN, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and ...